Category Archives: Healthcare

A Director at Aduro BioTech is Exercising Options

Yesterday it was reported that a Director at Aduro BioTech (ADRO – Research Report), Ross Haghighat, exercised options to buy 55,539 ADRO shares at $0.63 a share, for a total transaction value of $35.53K. Following this transaction Ross Haghighat’s holding

Chardan Capital Sticks to Its Hold Rating for IVERIC bio Inc (ISEE)

Chardan Capital analyst Gbola Amusa reiterated a Hold rating on IVERIC bio Inc (ISEE – Research Report) yesterday and set a price target of $1.25. The company’s shares closed last Monday at $1.11, close to its 52-week low of $1.02.

A Director at Adamas Pharmaceuticals is Exercising Options

Yesterday it was reported that a Director at Adamas Pharmaceuticals (ADMS – Research Report), David L. Mahoney, exercised options to buy 33,332 ADMS shares at $1.75 a share, for a total transaction value of $58.33K. The options were close to

Bluebird Bio (BLUE) Receives a Hold from William Blair

William Blair analyst Raju Prasad maintained a Hold rating on Bluebird Bio (BLUE – Research Report) today. The company’s shares closed last Monday at $107.04. According to TipRanks.com, Prasad is a 5-star analyst with an average return of 14.4% and

Zynerba Pharmaceuticals (ZYNE) Receives a Buy from Ladenburg Thalmann & Co.

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Zynerba Pharmaceuticals (ZYNE – Research Report), with a price target of $26. The company’s shares closed last Monday at $8.95. Higgins noted: “We

H.C. Wainwright Maintains Their Buy Rating on Beyondspring Inc (BYSI)

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Beyondspring Inc (BYSI – Research Report), with a price target of $41. The company’s shares closed last Monday at $19.14. Pantginis said: “Valuation and risks